期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 96, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.intimp.2021.107714
关键词
Low-dose naltrexone; Opioid receptor antagonist; Antitumor effect; Immunomodulation; Toll-like receptor
Naltrexone is a nonspecific opioid antagonist used in various disorders, while low-dose naltrexone demonstrates significant inhibition in cancer treatment and immune remodeling against tumor invasion and chemical toxicity, making it a focus of anticancer research.
Naltrexone (NTX) is a nonspecific opioid antagonist that exerts pharmacological effects on the opioid axis by blocking opioid receptors distributed in cytoplastic and nuclear regions. NTX has been used in opioid use disorder (OUD), immune-associated diseases, alcoholism, obesity, and chronic pain for decades. However, low-dose naltrexone (LDN) also exhibits remarkable inhibition of DNA synthesis, viability, and other functions in numerous cancers and is involved in immune remodeling against tumor invasion and chemical toxicity. The potential anticancer activity of LDN is a focus of basic research. Herein, we summarize the associated studies on LDN oncotherapy to highlight the potential mechanisms and prospective clinical applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据